First FDA authorization for next-generation sequencer.

The New England journal of medicine ·Vol. 369 ·No. 25 ·2013-12-19 ·Pages 2369-71

Collins FS, Hamburg MA

Abstract

暂无摘要

MeSH Terms

Device Approval/legislation & jurisprudence Genome, Human Humans Pharmacogenetics Precision Medicine Sequence Analysis, DNA/economics,instrumentation,methods United States United States Food and Drug Administration

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Collins Francis S

From the Office of the Director, National Institutes of Health, Bethesda, MD (F.S.C.); and the Office of the Commissioner, Food and Drug Administration, Department of Health and Human Services, Silver Spring, MD (M.A.H.).

Hamburg Margaret A

References (3)

3 references, click to expand

Genomics, health care, and society.
N Engl J Med. 2011 Sep 15;365(11):1033-41 PMID: 21916641
Mutational landscape and significance across 12 major cancer types.
Nature. 2013 Oct 17;502(7471):333-339 PMID: 24132290
Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
N Engl J Med. 2013 Dec 12;369(24):2345-6 PMID: 24251364

Article Info

Journal

The New England journal of medicine

Abbr.

N Engl J Med

ISSN

1533-4406

DOI

10.1056/NEJMp1314561

Published

2013-12-19

Epub

2013-00-19

Pages

2369-71

Language

English

Region

United States

NLM ID

0255562

PMCID

PMC5101955

Subset

External Links

PubMed source DOI: 10.1056/NEJMp1314561 PMC Full Text View journal details

Analysis Services

First FDA authorization for next-generation sequencer.

Contact

WeChat Official Account